SEOM-GEINO clinical guidelines for grade 2 gliomas (2023)

Clin Transl Oncol. 2024 Apr 25. doi: 10.1007/s12094-024-03456-x. Online ahead of print.

Abstract

The 2021 World Health Organization (WHO) classification has updated the definition of grade 2 gliomas and the presence of isocitrate dehydrogenase (IDH) mutation has been deemed the cornerstone of diagnosis. Though slow-growing and having a low proliferative index, grade 2 gliomas are incurable by surgery and complementary treatments are vital to improving prognosis. This guideline provides recommendations on the multidisciplinary treatment of grade 2 astrocytomas and oligodendrogliomas based on the best evidence available.

Keywords: Astrocytoma; Guideline; IDH mutation; Low-grade glioma; Neuro-oncology; Oligodendroglioma.